Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $216.6 million.

  • BridgeBio Pharma's Total Current Liabilities rose 55.59% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year increase of 55.59%. This contributed to the annual value of $154.4 million for FY2024, which is 7.34% up from last year.
  • Per BridgeBio Pharma's latest filing, its Total Current Liabilities stood at $216.6 million for Q3 2025, which was up 23.17% from $175.9 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Total Current Liabilities peaked at $216.6 million during Q3 2025, and registered a low of $94.7 million during Q1 2021.
  • Its 3-year average for Total Current Liabilities is $142.8 million, with a median of $141.5 million in 2024.
  • Per our database at Business Quant, BridgeBio Pharma's Total Current Liabilities dropped by 21.99% in 2023 and then spiked by 55.59% in 2025.
  • BridgeBio Pharma's Total Current Liabilities (Quarterly) stood at $135.1 million in 2021, then dropped by 10.10% to $121.4 million in 2022, then increased by 18.46% to $143.8 million in 2023, then rose by 7.34% to $154.4 million in 2024, then surged by 55.59% to $216.6 million in 2025.
  • Its Total Current Liabilities was $216.6 million in Q3 2025, compared to $175.9 million in Q2 2025 and $152.1 million in Q1 2025.